Suppr超能文献

胃和胃食管交界腺癌淋巴结转移肿瘤退缩的意义。

Significance of tumour regression in lymph node metastases of gastric and gastro-oesophageal junction adenocarcinomas.

机构信息

Department of Surgery, Klinikum Rechts der Isar, TUM School of Medicine, Munich, Germany.

Institute of Pathology, Technische Universität München, Munich, Germany.

出版信息

J Pathol Clin Res. 2020 Oct;6(4):263-272. doi: 10.1002/cjp2.169. Epub 2020 May 13.

Abstract

The presence of lymph node (LN) metastases is one of the most important negative prognostic factors in upper gastrointestinal carcinomas. Tumour regression similar to that in primary tumours can be observed in LN metastases after neoadjuvant therapy. We evaluated the prognostic impact of histological regression in LNs in 480 adenocarcinomas of the stomach and gastro-oesophageal junction after neoadjuvant chemotherapy. Regressive changes in LNs (nodular and/or hyaline fibrosis, sheets of foamy histiocytes or acellular mucin) were assessed by histology. In total, regressive changes were observed in 128 of 480 patients. LNs were categorised according to the absence or presence of both residual tumour and regressive changes (LN-/+ and Reg-/+). 139 cases were LN-/Reg-, 28 cases without viable LN metastases revealed regressive changes (LN-/Reg+), 100 of 313 cases with LN metastases showed regressive changes (LN+/Reg+), and 213 of 313 metastatic LN had no signs of regression (LN+/Reg-). Overall, LN/Reg categorisation correlated with overall survival with the best prognosis for LN-/Reg- and the worst prognosis for LN+/Reg- (p < 0.001). LN-/Reg+ cases had a nearly significant better outcome than LN+/Reg+ (p = 0.054) and the latter had a significantly better prognosis than LN+/Reg- (p = 0.01). The LN/Reg categorisation was also an independent prognostic factor in multivariate analysis (HR = 1.23; 95% CI 1.1-1.38; p < 0.001). We conclude that the presence of regressive changes after neoadjuvant treatment in LNs and LN metastases of gastric and gastro-oesophageal junction cancers is a relevant prognostic factor.

摘要

淋巴结(LN)转移的存在是上消化道癌最重要的负预后因素之一。新辅助治疗后,LN 转移中可观察到类似于原发肿瘤的肿瘤退缩。我们评估了 480 例胃和胃食管交界处腺癌患者新辅助化疗后 LN 组织学消退的预后影响。通过组织学评估 LN(结节和/或透明样纤维化、泡沫状组织细胞片或无细胞粘蛋白)的退行性变化。在 480 例患者中,共有 128 例观察到退行性变化。根据是否存在残留肿瘤和退行性变化,将 LN 分类(LN-/+和 Reg-/+)。139 例为 LN-/Reg-,28 例无存活 LN 转移的患者显示退行性变化(LN-/Reg+),313 例有 LN 转移的患者中有 100 例显示退行性变化(LN+/Reg+),313 例转移性 LN 中有 213 例无退行性变化(LN+/Reg-)。总的来说,LN/Reg 分类与总生存率相关,LN-/Reg-的预后最好,而 LN+/Reg-的预后最差(p<0.001)。LN-/Reg+病例的预后明显好于 LN+/Reg+(p=0.054),后者的预后明显好于 LN+/Reg-(p=0.01)。在多变量分析中,LN/Reg 分类也是一个独立的预后因素(HR=1.23;95%CI 1.1-1.38;p<0.001)。我们得出结论,新辅助治疗后胃和胃食管交界处癌症的 LN 和 LN 转移中存在退行性变化是一个相关的预后因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e3ff/7578278/da87bc569271/CJP2-6-263-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验